CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Stock Short Interest Drops 69.8%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 898 shares, a drop of 69.8% from the September 15th total of 2,969 shares. Based on an average daily trading volume, of 3,007 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the shares of the company are short sold.

CNS Pharmaceuticals Trading Down 4.7%

Shares of CNSP traded down $0.25 during mid-day trading on Monday, reaching $5.10. 6,198 shares of the stock traded hands, compared to its average volume of 472,594. The company has a market cap of $7.45 million, a price-to-earnings ratio of -0.22 and a beta of 3.10. The firm has a fifty day moving average price of $5.49 and a 200 day moving average price of $4.72. CNS Pharmaceuticals has a 1 year low of $1.90 and a 1 year high of $10.54.

Get CNS Pharmaceuticals alerts:

CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14).

Institutional Investors Weigh In On CNS Pharmaceuticals

An institutional investor recently bought a new stake in CNS Pharmaceuticals stock. ADAR1 Capital Management LLC purchased a new stake in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 70,000 shares of the company’s stock, valued at approximately $335,000. ADAR1 Capital Management LLC owned about 4.79% of CNS Pharmaceuticals as of its most recent SEC filing. 14.02% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Get Our Latest Stock Analysis on CNSP

About CNS Pharmaceuticals

(Get Free Report)

CNS Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing treatments for primary and metastatic cancers of the brain and central nervous system. The company’s research is centered on therapies designed to address the challenges of delivering effective medicines across the blood-brain barrier.

Its lead product candidate is berubicin, an anthracycline designed to penetrate the blood-brain barrier and target malignant brain tumors. CNS Pharmaceuticals has primarily investigated berubicin as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer with limited treatment options.

Featured Stories

• Five stocks we like better than CNS Pharmaceuticals
• Salesforce Just Got a Rare Double Upgrade—What Changed?
• OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
• China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
• 3 REITs That May Win in a Higher Interest Rate Environment

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.